Updated on 18 June 2013
"In the absence of consensus, a final decision on the issue may take from couple of months to several years. Therefore, it is not feasible to furnish any tangible time period at present. The final decision on the matter, whenever available will be put up in public domain," she had mentioned.
Though the industry may not very happy about it, Dr Annadana, sees a ray of hope in the minister's words. He says, "At least she has mentioned that biosafety is the only concern and I feel that we should agree with her on that count. Nobody would like to release an unsafe product in the market. Its just that scientifically sound justification must be given while rejecting the applications or stalling the ongoing trials."
Dr V R Kaundinya, managing director, Advanta India, feels that the regulatory policy has to be conducive for investments. "Regulatory policy is not a static policy. It needs to be upgraded with time and it must be done immediately," he said.
With the GEAC back in business again, it is expected that the industry-at least for the time being-can look up to some agency for the clearances and redressal of issues. Having so much investments at stake in various field trials, the decision, no doubt will help the regulatory body to get back on track yet again.